ライフサイエンスコーパス: healthy donor

1 progenitor cells (hCB-EPCs) from a separate, healthy donor.

2 ds and to primary macrophages derived from a healthy donor.

3 a large number of commensal microbes from a healthy donor.

4 ic T cells from patients with CTCL than from healthy donors.

5 130) were compared to 733 antibodies from 15 healthy donors.

6 e sections of COPD patients when compared to healthy donors.

7 in plasma collected from HIV-1-infected and healthy donors.

8 a secondary screen against human serum from healthy donors.

9 roblasts compared with lung fibroblasts from healthy donors.

10 ons was performed in 46 CVID patients and 44 healthy donors.

11 T cell repertoire using PBMCs collected from healthy donors.

12 HLA can be found in the T-cell repertoire of healthy donors.

13 ultipotent stromal cells (MSCs) derived from healthy donors.

14 microbiota transplantation (FMT) provided by healthy donors.

15 types of myelodysplastic syndromes (MDS) and healthy donors.

16 spirates, including 16 AML patients and five healthy donors.

17 nd established RA cohorts in comparison with healthy donors.

18 d cGVHD, compared with those who did not and healthy donors.

19 elevated in COVID-19 patients compared with healthy donors.

20 -Cas9 in induced pluripotent stem cells from healthy donors.

21 ukemia activity, from Ph(+) ALL patients and healthy donors.

22 d indistinctly with platelets from different healthy donors.

23 with anti-viral T cells, and with those from healthy donors.

24 normal bone marrow CD34(+) progenitors from healthy donors.

25 was little or no expression in synovium from healthy donors.

26 ar cells (PBMCs) were isolated from blood of healthy donors.

27 a tendency to overexpress CCR2 compared with healthy donors.

28 anisms in isolated human CD4(+) T cells from healthy donors.

29 tained at day 3 and compared with those from healthy donors.

30 nts with Myelodysplastic syndromes (MDS) and healthy donors.

31 skin biopsies and blood draws obtained from healthy donors.

32 and lower levels of AXL compared to DC from healthy donors.

33 kin samples from patients with psoriasis and healthy donors.

34 id arthritis and compared with synovium from healthy donors.

35 man peripheral blood monocytes isolated from healthy donors.

36 VHD compared with patients without cGVHD and healthy donors.

37 -FD and FD are present in the circulation of healthy donors.

38 performed on 29 patients with sepsis and 15 healthy donors.

39 ry arterial hypertension (IPAH) patients and healthy donors.

40 ssions were analysed on human basophils from healthy donors.

41 2 polarization of CD8(+) T cells (TC2) from healthy donors.

42 t the ex vivo manufacture of multi-VSTs from healthy donors.

43 feration with CD40 stimulation compared with healthy donors.

44 ls carrying this mutation in CLL patients or healthy donors.

45 ytes from 23 APS and 64 SLE patients, and 56 healthy donors.

46 a therapeutic preparation of pooled IgG from healthy donors.

47 rotein involved in iron acquisition, in four healthy donors.

48 significantly higher (P = 0.04) than that of healthy donors.

49 ases versus patients who received blood from healthy donors.

50 eutrophils were lower in APS and SLE than in healthy donors.

51 cell lines compared to primary B cells from healthy donors.

52 embled those for peripheral blood cells from healthy donors.

53 CTCL cell lines, but hardly in T cells from healthy donors.

54 subjects with prostate cancer compared with healthy donors.

55 with MM secreted higher amounts of IL-8 than healthy donors.

56 iversity and composition to resemble that of healthy donors.

57 s patients as compared to blood samples from healthy donors.

58 able or higher specificities than using Thai healthy donors.

59 ients with COVID-19 and SARS-CoV-2-unexposed healthy donors.

60 ory Treg subsets was similar in patients and healthy donors.

61 mmune response against gB, gH, and gL within healthy donors.

62 ts whose tumors did not metastasize), and 37 healthy donors.

63 ssion profiling of 40 Treg cell subsets from healthy donors.

64 ver 5 time points and compared the values to healthy donors.

65 ity and sporulation were rescued by OME with healthy donors.

66 om patients with HPV(-) and HPV(+) HNSCC and healthy donors.

67 enitor frequency in blood was higher than in healthy donors.

68 d and applied on a serum sample set from 185 healthy donors.

69 of patients with COVID-19 but also in 35% of healthy donors.

70 gher in pediatric B-ALL patients compared to healthy donors.

71 ansplantation (FMT), using feces provided by healthy donors.

72 gical treatment and in 40 sera obtained from healthy donors.

73 more exosomes from NSCLC patients than from healthy donors.

74 7 of the 34 patients, but less frequently in healthy donors.

75 ptome and translatome in septic patients and healthy donors.

76 ratio of CD4+ T cells to CD8+ T cells and 11 healthy donors.

77 were purified from self-reported allergic or healthy donors.

78 mellitus and hypertension) as compared with healthy donors.

79 ow) (9/41) B cells compared with age-matched healthy donors (1/33 and 2/33, respectively), which indi

80 patients who received fecal transplants from healthy donors (41.2%) and 5 of 20 controls (25.0%) achi

81 of reduced expression of CD39 compared with healthy donors, a marker for the highly suppressive TREM

82 F tissue culture experiments were done using healthy donor and IPF lungs.

83 of cytomegalovirus-specific CD8 T cells from healthy donor and patient after haploidentical stem cell

84 duced pluripotent stem cells (hiPSCs) from a healthy donor and patients with SVs.

85 fore and after DAA therapy, and also from 12 healthy donors and 12 individuals with HCV infection wit

86 Blood from 46 healthy donors and 120 patients with peanut allergy was

87 sequencing in peripheral blood samples of 5 healthy donors and 13 patients with COVID-19, including

88 he sensor is demonstrated in cellular lines, healthy donors and a cancer patient.

89 s reside in bone marrow, hardly circulate in healthy donors and are absent in cord blood.

90 ade from the pooled plasma from thousands of healthy donors and are being tested in preclinical mouse

91 cells but is absent in resting T cells from healthy donors and B-cell lymphoma cells.

92 reliable results for the differentiation of healthy donors and breast cancer individuals based on sp

93 Although CD4(+) T(H) cell profiles from healthy donors and CVID subjects without AICs were virtu

94 esponse to all 7 PIV3-encoded antigens in 17 healthy donors and define a hierarchy of immunogenicity

95 plored using human endothelium isolated from healthy donors and donors with obesity/type 2 diabetes m

96 Both CD8+ and CD4+ T cells from healthy donors and from chronic hepatitis B patients bec

97 cultured human skin fibroblasts derived from healthy donors and from patients with progeria, a geneti

98 CSWB was evaluated in blood from healthy donors and from women with metastatic breast can

99 CD8), using clinically accessible blood from healthy donors and MS patients in the initial relapsing-

100 g blood mononuclear cells isolated from both healthy donors and MSI-H cancer patients.

101 ated peripheral blood mononuclear cells from healthy donors and observed that PA strains induce highe

102 eased IFN-gamma production, compared to both healthy donors and paired 90-day samples.

103 ed and characterized by culturing PBMCs from healthy donors and patients with a history of clozapine-

104 within the viral-specific Th1 repertoire of healthy donors and patients with acute myeloid leukemia

105 nhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis

106 ipheral blood mononuclear cells (PBMCs) from healthy donors and patients with ASD.

107 early- and late-stage pancreatic cancer from healthy donors and patients with benign pancreatic disea

108 f tendon-derived stromal cells isolated from healthy donors and patients with chronic tendinopathy.

109 ntation bisulfite sequencing to B cells from healthy donors and patients with CLL.

110 Compared with healthy donors and patients with HCV infection without C

111 , were performed using peripheral blood from healthy donors and patients with IPF and A549 cells.

112 bits fibrocyte differentiation from blood of healthy donors and patients with IPF.

113 d by bronchoscopy from bronchial biopsies of healthy donors and patients with mild and severe asthma.

114 Blood obtained from healthy donors and patients with PDAC was therefore subj

115 ultures of primary human CD4(+) T cells from healthy donors and patients with type 1 diabetes or Seza

116 H and L chains, with similar frequencies for healthy donors and patients.

117 Human HPCs from healthy donors and pediatric patients proliferated vigor

118 rated in activated human CD4(+) T cells from healthy donors and RA patients.

119 Blood from healthy donors and SLE patients have similar circulating

120 te-derived macrophages (HMDMs) obtained from healthy donors and SLE patients.

121 lated from wild-type mice or cord blood from healthy donors and submitted to polarizing cytokines, wi

122 with UC who received fecal transplants from healthy donors and those who received their own fecal mi

123 C) were investigated, using cells from three healthy donors and three COPD patients, cultured under A

124 orming a blind analysis of blood smears from healthy donors and thrombocytopenic and sickle cell dise

125 PBMCs from healthy donors and/or respiratory epithelial cells were

126 effective against the fungus than those from healthy donors, and broader heterogeneity exists between

127 y was proven in plasma from CRC patients and healthy donors, and full discrimination between mutated

128 s, co-localizes with antigen on B cells from healthy donors, and is present on antigen-positive B cel

129 d serum samples of xenotransplanted mice, of healthy donors, and of patients with uveal melanoma duri

130 gnificantly reduced in frequency compared to healthy donors, and were more activated, with decreased

131 Furthermore, HM exosomes from healthy donors are known to inhibit HIV-1 infection and

132 Six samples from three healthy donors are profiled and high-quality RNA-seq dat

133 pheral blood lymphocytes (PBLs) derived from healthy donors as well as chronically infected HCV patie

134 sequencing data using blood-derived DNA from healthy donors as well as DNA from tumor samples, we pre

135 oduction by human memory CD4(+) T cells from healthy donors, as assessed by intracellular cytokine st

136 ubjects provided efficient help to receptive healthy donor B cells but not unresponsive CVID B cells.

137 Stimulation of healthy donor B cells with CD40L, anti-IgM, IL-21, CpG,

138 g in 57 WM patients and compared findings to healthy donor B cells.

139 xpression and DNAme in 22 primary CLL and 13 healthy donor B lymphocyte samples.

140 ected a baseline of 2-5 CD138(+) cells/mL in healthy donor blood, with significantly higher numbers i

141 mparison of CSF1R-expressing cells in AML vs healthy donors by mass cytometry revealed expression of

142 sulforaphane ex vivo treatment in PBMCs from healthy donors by real-time quantitative PCR.

143 ells were generated from peripheral blood of healthy donors by stimulation with overlapping peptide l

144 Transfer of these TCRs to healthy donor CD4+ T cells conferred high antigen sensit

145 w diminished levels of miR-29b compared with healthy donor cells.

146 Among healthy donors, circulating TCR sequence diversity remai

147 LAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity.

148 collected samples of ILD tissue (n = 45) and healthy donor control samples (n = 10), as well as fibro

149 cells of RRMS patients at levels similar to healthy donor controls.

150 65) following CD40 stimulation compared with healthy donor controls.

151 ory B cell responses (MBC) in APTB cases and healthy donor controls.

152 still recognize I/i antigens, whereas their healthy donor counterparts harbored FWR1 mutations aboli

153 ompared with about 18 mutations per clone in healthy-donor counterparts.

154 expression gene network between diabetic and healthy donor-derived ECs corroborate the H + T-induced

155 roke patients inhibited the proliferation of healthy donor-derived lymphocytes, an effect which was a

156 Transplanting healthy donor-derived microbiotas into mice colonized wi

157 mulated ADAM17-dependant CD163 shedding from healthy donor-derived monocytes.

158 Replacement of the diseased cells with a healthy donor endothelium is the only currently availabl

159 IFN-gamma secretion assay from HLA-unmatched healthy donors exhibited a high level of anti-CMV potenc

160 sing peripheral blood mononuclear cells from healthy donors exposed to IFN-alpha and chronic hepatiti

161 idosis patients from Thailand along with 188 healthy donors from Thailand and 90 healthy donors from

162 with 188 healthy donors from Thailand and 90 healthy donors from the United States as controls.

163 on of a cluster of inflammatory mediators in healthy donor GFs (IL1B, CCL2, CCL5, CXCL10, COX2, and M

164 identified by comparing cancer patients' and healthy donors' global peptide profiles of antibody spec

165 light chain (NFL), were elevated compared to healthy donor (HD) controls.

166 Patient and matched healthy donor (HD) sera were derived from four large coh

167 and the cytotoxic potential of NK cells from healthy donors (HD) and CP.

168 xicity in PBMC from CLL patients compared to healthy donors (HD).

169 is of myoglobin (Mb) in 10 plasma samples of healthy donors (HDs) and 14 plasma samples of patients w

170 lated and characterized from BM aspirates of healthy donors (HDs) and BT patients.

171 their potential as immunological markers in healthy donors (HDs) and patients with rheumatoid arthri

172 oV-NL63, and HCoV-OC43) and SARS-CoV-2 in 21 healthy donors (HDs) who were seronegative for SARS-CoV-

173 Samples from 14 healthy donors (HDs), 40 PHI patients, 17 Chronics, and

174 from plasma of 12 melanoma patients and six healthy donors (HDs).

175 Our findings demonstrate that healthy donor HSPC not only reconstitute the hematopoiet

176 ree IGHV4-34*01 IgG antibodies isolated from healthy donors immunized against foreign rhesus D alloan

177 stromal cells (MSCs) to these patients from healthy donors in a double-blind, placebo-controlled stu

178 al infarction (AMI) and in control plasma of healthy donors in order to demonstrate the potential med

179 activation of primary KIR2DL3+ NK cells from healthy donors in response to HLA-C*03:04+ target cells

180 upplemented with concentrated platelets from healthy donors in vitro, raising platelet counts by 0% (

181 play marked subject variability in sera from healthy donors incubated at 37 degrees C.

182 ipheral blood mononuclear cells (PBMCs) from healthy donors incubated with infliximab or infliximab-T

183 phils were purified from peripheral blood of healthy donors, incubated with interleukin 5, cocultured

184 ation-the transfer of prescreened stool from healthy donors into the gastrointestinal tract of patien

185 cal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysb

186 Fecal transfer from healthy donors is being explored as a microbiome modalit

187 n addition, the use of a pool of faeces from healthy donors is strongly recommended to improve repeat

188 added to lepirudin-anticoagulated blood from healthy donors, it significantly reduced the uptake of S

189 ection bias of transplanting only relatively healthy donor kidneys with AKI.

190 igh-avidity CD8+ T cell clones isolated from healthy donors killed CBFB-MYH11+ HLA-B*40:01+ AML cell

191 ll response was demonstrated in 18 of the 23 healthy donors, leading to the generation of 70 independ

192 ody-predicted structural models across three healthy donors led to a number of key findings: (i) VH a

193 cleavage and TLR4 signaling intermediates in healthy donor leukocytes and either a TLR4 inhibitor or

194 and inhibitory receptor repertoire to normal healthy donor levels.

195 positive versus HCV-negative HCC patients or healthy donor livers.

196 s lymphocytes compared to those grafted with healthy donors lymphocytes.

197 ng/mL [range, 201-469 ng/mL]) (P < .001) and healthy donors (median level, 285 ng/mL [range, 65-463 n

198 s-mediated apoptosis could be transferred to healthy donor memory B-cells by co-culturing these cells

199 s showed similar (MS patients) or increased (healthy donors) MHC-II expression as class-switched memo

200 tors (MkPs) are transcriptionally similar to healthy-donor MkPs, but the majority are disease specifi

201 ephron size, and smaller medullary volume in healthy donors modestly predict death-censored graft fai

202 HLA-DR, CD80, CD86, and PD-L1 expression on healthy donor monocytes.

203 itis C virus-infected patients (n = 17), and healthy donors (n = 173).

204 rotocol validation was assessed in saliva of healthy donors (n = 21) by enzyme-linked immunosorbent a

205 ared them with patients with KS (n = 24) and healthy donors (n = 29).

206 ted by other flaviviruses, other viruses, or healthy donors (n = 540), the specificity was 95.9%.

207 linical atherosclerosis patients (n = 8) and healthy donors (n = 8) in the LVAD study (NCT02174133, N

208 Studying FcgammaRIIIb derived from healthy donor neutrophils, we observed profound differen

209 e CTCL cell line SeAx, but not in T cells of healthy donors nor in the CTCL cell line HH, which lacks

210 e cells (CD4(+) T cells) to HCMV proteins in healthy donors of all ages, and we demonstrate that the

211 ore, we developed a new paradigm by grafting healthy donor or multiple sclerosis patient lymphocytes

212 neering of peripheral blood lymphocytes from healthy donors or chronically infected HCV patients resu

213 henotype inexperienced cells, as compared to healthy donors or cured HCV patients.

214 numbers than seen in the peripheral blood of healthy donors or in patients before transplant.

215 IGHT that were expressed by fibroblasts from healthy donors or patients with active EoE.

216 e isolated from esophageal biopsy samples of healthy donors or patients with active EoE.

217 re obtained from bronchoalveolar lavage from healthy donors or patients with COPD and challenged with

218 seq in T cell and B cell subsets from either healthy donors or patients with SLE.

219 to groups that underwent FMT with feces from healthy donors or were given autologous fecal microbiota

220 en after a damaged kidney is replaced with a healthy donor organ.

221 inhibitory effect was observed in PBMCs from healthy donors over a range of concentrations of sorafen

222 1-mutation carriers compared with cells from healthy donors (p = 0.0014).

223 s had higher number of HER2 gene copies than healthy donors (p = 0.0016).

224 naive B cells in NMOSD patients compared to healthy donors (P-values < 0.003), thereby identifying d

225 We analyzed blood and feces from healthy donors, patients with selective IgA deficiency (

226 ng and evaluated them by T cell assays using healthy donor PBMCs.

227 rve no impact of isoflavones on viability of healthy donor peripheral blood mononuclear cells (PBMCs)

228 in vitro, healthy donor peripheral blood mononuclear cells, purifi

229 PMPs were cocultured with healthy donor peripheral blood-derived Tregs that were s

230 In healthy donors, PF4/heparin complexes bind preferentiall

231 was purified and added to closed ADAMTS13 in healthy donor plasma.

232 l IgG formulation prepared from thousands of healthy donors' plasma, is extensively used for the immu

233 and dendritic cells from peripheral blood of healthy donors produce IL-12 and other proinflammatory c

234 n the FMT group was similar to that of their healthy donors; remission was associated with proportion

235 T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal reg

236 to combine the gene expression in a STEMI vs healthy donors score showed an AUC of 0.95.

237 nfirmed coronavirus disease 2019 (COVID-19), healthy donor sera from 2018, and a cross-reactivity ser

238 e probed by using Western blot analysis with healthy donor sera.

239 knowledge gap, we obtained plasma from four healthy donors serially sampled five times during 12 h i

240 T cell responses from healthy donors showed a high degree of cross-reactivity

241 l subsets and TCR variable beta classes from healthy donors showed polytypic TRBC1 staining.

242 ed by the availability of a suitable area of healthy donor skin to harvest.

243 Blood and urine samples from healthy donors spiked with cfDNA from Mycobacterium tube

244 om patients with T1D but scantly detected in healthy donor subjects.

245 ased CYP1A1 enzymatic activity compared with healthy donors, suggesting that dysregulation of the AHR

246 heumatoid arthritis patients than those from healthy donors, suggesting that VR23 can be selective ag

247 estricted by the lack of biliary tissue from healthy donors suitable for surgical reconstruction.

248 nduction of neoepitope-reactive T cells from healthy donor T cell repertoires, unaffected by the pote

249 Compared with healthy donors, T-cell expanded in peripheral repertoire

250 ells isolated from human PBMCs obtained from healthy donors that had been stimulated by their respect

251 eripheral blood mononuclear cells (PBMCs) of healthy donors that ultimately leads to removal from the

252 bsets from patients with type 1 diabetes and healthy donors, that patients have shorter TCRB compleme

253 ipheral blood mononuclear cells (PBMCs) from healthy donors to distinguish cell-type-specific inter-i

254 cell quality and in cell-banked sourcing of healthy donors to enable "off-the-shelf" products.

255 used retrospective serial blood samples from healthy donors to investigate this topic.

256 xposed purified NK cells and full PBMCs from healthy donors to PLT-Ecto.

257 We validated this strategy using cells from healthy donors to retrieve human antibodies against teta

258 Compared to microbiotas from healthy donors, transfer of IBD microbiotas into germ-fr

259 ART1-specific CD8 T cells were expanded from healthy donors using artificial APCs.

260 iron accumulation in lung tissue sections of healthy donors versus severe COPD patients.

261 rded attomolar concentrations of IFNalpha in healthy donors, viral infection, and complex and monogen

262 ith dementia versus recipients of blood from healthy donors was 1.04 (95% CI, 0.99 to 1.09).

263 tal Th cells or different Th cell subsets of healthy donors was analyzed in vitro.

264 ROCC) to discriminate melioidosis cases from healthy donors was highest for anti-Hcp1 IgG (0.92) comp

265 rity-matched intensive care patients, and 67 healthy donors was prospectively enrolled for flow cytom

266 Blood from healthy donors was subjected to processing delays common

267 icipants 14 to 21 days after AMI and BM from healthy donors was used as a reference.

268 Using primary human blood monocytes from healthy donors, we identified ANXA1 as a potent CD14(+)C

269 e acute response to influenza vaccination in healthy donors, we identify the presence of phenotypic C

270 Using 12 saliva samples from healthy donors, we modified the methodology to (1) selec

271 m the same patients 15 days after FMT from a healthy donor were also pooled (post-FMT).

272 Samples from five healthy donors were analysed and 150 differential coloni

273 rticle-depleted plasma samples from the same healthy donors were analyzed in parallel.

274 Isolated circulating basophils from healthy donors were cultured in the presence of IL-3, IL

275 Peripheral blood mononuclear cells from healthy donors were cultured with Mycobacterium tubercul

276 Fifty-seven patients and 20 healthy donors were enrolled.

277 T cells in PBMC from healthy donors were expanded with peptide and IL-2 or tr

278 murine splenocytes and from blood samples of healthy donors were incubated for 8 days under Th2-like

279 eral blood mononuclear cells (PBMCs) from 20 healthy donors were infected in vitro with HIV-1BaL in t

280 Spike-reactive CD4(+) T cells in healthy donors were primarily active against C-terminal

281 Highly purified neutrophils from healthy donors were primed in vitro with a papillary TC

282 plasma samples from melioidosis patients and healthy donors were quantified by ELISA and compared wit

283 s in peripheral blood mononuclear cells from healthy donors were stimulated with anti-CD3 and anti-CD

284 ls freshly isolated from peripheral blood of healthy donors were stimulated with different combinatio

285 Stool specimens from healthy donors were treated with ethanol to eliminate pa

286 In addition, 8 eyeballs from healthy donors were used for biochemical analysis.

287 es from 68 individuals (58 PDAC patients, 10 healthy donors) were analyzed; CTCs were present in pati

288 higher prothrombin and factor X levels than healthy donors, whereas levels were unchanged in primary

289 min induced NETs release by neutrophils from healthy donors which was not suppressed by inhibitors of

290 work, we found that semen exosomes (SE) from healthy donors who do not use illicit drugs potently inh

291 Priming of naive T cells from healthy donors with aberrant peptides induced peptide-sp

292 An AUC of 0.73 was obtained when comparing healthy donors with biopsy-positive patients.

293 queried HHV-6B-specific CD4 T cells from 18 healthy donors with each known HHV-6B protein.

294 e studied NET production in neutrophils from healthy donors with inhibitors of molecules crucial to P

295 n-10-producing dendritic cells obtained from healthy donors with peripheral blood mononuclear cells (

296 etic stem and progenitor cells obtained from healthy donors, with CRISPR-Cas9 targeting the BCL11A er

297 es similar to bona fide T(SCM) isolated from healthy donors, with intermediate characteristics compar

298 tokine patterns were shared among a group of healthy donors, with minimal intraindividual and interin

299 enhances the manufacture of multi-VSTs from healthy donors without altering their phenotype or funct

300 Compared with healthy donors, WM patient samples showed greatly enhanc